

Amendments to the Specification:

Please replace the paragraph beginning at page 5, line 29, with the following:

--According to another aspect, the monomeric analogue is the INSL3 analogue designated ~~eINSLa~~ cINSL3a in Figure 3.--

Please replace the paragraph beginning at page 6, line 1, with the following:

--In a further aspect, the monomeric analogue is the INSL3 analogue designated ~~eINSLb~~ cINSL3b in Figure 3.--

Please replace the paragraph beginning at page 7, line 17, with the following:

--In a preferred form, the method produces the INSL3 analogue designated ~~eINSLa~~ cINSL3a in Figure 3.--

Please replace the paragraph beginning at page 7, line 20, with the following:

--In another preferred form, the method produces the INSL3 analogue designated ~~eINSLb~~ cINSL3b in Figure 3.--

Please replace the paragraph beginning at page 10, line 4, with the following:

--FIGURE 1: Schematic representation of binding of INSL3, ~~eINSLa~~ cINSL3a and ~~eINSLb~~ cINSL3b analogues to the LGR8 receptor.--

Please replace the paragraph beginning at page 10, line 7, with the following:

--FIGURE 3: Sequences and constraints of the native relaxin (SEQ ID NO:2) and ~~INSL3~~
~~B-chains~~ INSL3 B-chains (SEQ ID NO:7) with exemplary analogues (SEQ ID NOS:11-13)
designed.--

Please replace the paragraph beginning at page 10, line 13, with the following:

--FIGURE 4: Schematic representation of antagonistic activity of ~~eINSLa~~ cINSL3a in the
inhibition of the response of INSL3 (measured by cAMP response) to the native INSL3 receptor
(LGR8).--

Please replace the paragraph beginning at page 10, line 17, with the following:

--FIGURE 5: Schematic representation illustrating CD spectra of ~~eINSLa~~ cINSL3a
showing significant alpha-helical content in water and phosphate buffered saline.--

Please replace the paragraph beginning at page 12, line 15, with the following:

--In a particularly preferred aspect, the B-chain peptide analogue is the INSL3 analogue
designated ~~eINSLa~~ cINSL3a in Figure 3.--

Please replace the paragraph beginning at page 12, line 18, with the following:

--In yet another preferred form, the B-chain peptide analogue is the INSL3 analogue
designated ~~eINSLb~~ cINSL3b in Figure 3.--

Please replace the paragraph (TABLE A) beginning at page 15, line 15, with the following:

--TABLE A

CONSERVATIVE SUBSTITUTIONS I

Side Chain Characteristic	Amino Acid
Aliphatic non-polar	G A P I L V <u>G, A, P, I, L, V</u>
Polar — uncharged	G S T M N Q C <u>C, S, T, M, N, Q</u>
Polar — charged	D E K R <u>D, E, K, R</u>
Aromatic	H F W Y <u>H, F, W, Y</u>
Other	N Q D E <u>N, Q, D, E</u>

--

Please replace the paragraph (**TABLE B**) beginning at page 15, line 26, with the following:

--TABLE B

CONSERVATIVE SUBSTITUTIONS II

Side Chain Characteristic	Amino Acid
Non-polar (hydrophobic)	
A. Aliphatic:	A <u>L</u> <u>I</u> <u>V</u> <u>P</u> <u>A</u> , <u>L</u> , <u>I</u> , <u>V</u> , <u>P</u>
B. Aromatic:	F <u>W</u> <u>F</u> , <u>W</u>
C. Sulphur-containing:	M
D. Borderline:	G
Uncharged-polar	
A. Hydroxyl:	S <u>T</u> <u>Y</u> <u>S</u> , <u>T</u> , <u>Y</u>
B. Amides:	N <u>Q</u> <u>N</u> , <u>Q</u>
C. Sulfhydryl:	C
D. Borderline:	G
<u>E</u> . Positively Charged (Basic):	K <u>R</u> <u>H</u> <u>K</u> , <u>R</u> , <u>H</u>
<u>F</u> . Negatively Charged (Acidic):	D <u>E</u> <u>D</u> , <u>E</u>

Please replace the paragraph beginning at page 23, line 6, with the following:

--Using SYBYL molecular modelling software (Tripos) on a Silicon Graphics O2 workstation, we designed a model of INSL3 B-chain from the X-ray crystal structure of human Gene 2 relaxin B-chain as a template (Eigenbrot *et al.*, 1991, *J Mol Biol* 221: 15-21). After modifying the sequence to resemble that of INSL3, an energy minimisation using a Tripos forcefield with Gasteiger-Marsili charges was carried out. From the resulting energy minimised model, two residues were identified (Glu⁴ and Arg²⁶) to have C β atoms within 4Å of each other.

These residues were then replaced with cysteine and a disulphide bond formed to give the cyclic peptide ~~eINSLa~~ cINSL3a.--

Please replace the paragraph beginning at page 23, line 15, with the following:

--A second cyclic analogue ~~eINSLb~~ cINSL3b was formed by changing His¹² to Arg, to mimic a relaxin-like binding motif of Arg-X-X-Arg-X-X-X-Val.--

Please replace the paragraph beginning at page 25, line 27, with the following:

--Following the biological characterisation of peptides cRlx and ~~eINSLa~~ cINSL3a (Figure 3), an additional compound was prepared incorporating the Cys to Cys constraint of peptide ~~eINSLa~~ cINSL3a. This compound, designated ~~eINSLb~~ cINSL3b, was a INSL3-based sequence, in which ~~His¹² from~~ His¹² from the INSL3 sequence was replaced by Arg in an attempt to obtain an analogue of the putative relaxin receptor binding cassette ~~which is~~ absent in INSL3.--

Please cancel the present "SEQUENCE LISTING", pages 2-12, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 8, at the end of the application.